Posard Matthew L.: insider trades.
Posard Matthew L. reported 4 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($2.0M), across 1 company.
- Transactions
- 4
- Purchases (P)
- 0
- Sales (S)
- 4
- Companies
- 1
- Name as filed
- Posard Matthew L.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | Director | 4 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-16 | Halozyme Therapeutics, Inc. | S | 3,000 | $106.83 | 71,735 | Form 4 |
| 2026-09-16 | Halozyme Therapeutics, Inc. | S | 8,896 | $108.04 | 62,839 | Form 4 |
| 2026-09-16 | Halozyme Therapeutics, Inc. | S | 3,100 | $106.13 | 74,735 | Form 4 |
| 2026-09-16 | Halozyme Therapeutics, Inc. | S | 4,000 | $108.99 | 58,839 | Form 4 |
Questions
What stock did Posard Matthew L. buy or sell?
Posard Matthew L. reported 4 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($2.0M), across 1 company.
Is Posard Matthew L. the same person as other filers with this name?
This page covers SEC CIK 1543792 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/posard-matthew-l-1543792.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.